Chronic Kidney Disease: Emerging Mechanisms, Consequences and Targeted Treatments
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya and Maria Chiara Magnone
In Person
On Demand
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya and Maria Chiara Magnone
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Booking Function
Thursday, January 1, 2026
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Friday, January 2, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Katherine R. Tuttle †, University of Washington
Trials targeting the Cardiovascular Kidney Metabolic Syndrome: Finally Breaking the Death Spiral of CKD
Trials targeting the Cardiovascular Kidney Metabolic Syndrome: Finally Breaking the Death Spiral of CKD
CKD Function and Failure; From Models to Man
9:00–11:15 AM
Melissa Hallow †, University of Georgia
Modelling Kidney Function: What Renal Physiology Teaches us in 2025 for CKD
Modelling Kidney Function: What Renal Physiology Teaches us in 2025 for CKD
Melissa Little †, Murdoch Children's Research Institute
Kidney Organoids: Lessons and Opportunities for CKD Research and Drug development
Kidney Organoids: Lessons and Opportunities for CKD Research and Drug development
Jonathan Himmelfarb †, Mount Sinai School of Medicine
Evaluating Organ Cross Talk in CKD, ex vivo on a Chip
Evaluating Organ Cross Talk in CKD, ex vivo on a Chip
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Unraveling the Molecular Machinery of the Nephron in Function and Failure
5:00–7:00 PM
Aviv Regev †, Genentech
From Cells to Systems: How the Human Cell Atlas is Developing the Framework to Map Organ Cross Talk
From Cells to Systems: How the Human Cell Atlas is Developing the Framework to Map Organ Cross Talk
Laura Barisoni †, Duke University
Redefining CKD in Structural Term: AI Driven Image Analysis of the Kidney
Redefining CKD in Structural Term: AI Driven Image Analysis of the Kidney
Olga G. Troyanskaya, Princeton University
From Genes to Function to Failure: Systems Biology of CKD
From Genes to Function to Failure: Systems Biology of CKD
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Saturday, January 3, 2026
Breakfast
7:00–8:00 AM
CKD in Obesity and Diabetes: Driving the Disease Burden in the Cardio Metabolic Pandemic
8:00–11:00 AM
Tamer Coskun †, Eli Lilly & Company
Obesity Driven Metabolic Reprogramming: From Metabolic Profiling to Drug Targets for Cardiorenal Disease
Obesity Driven Metabolic Reprogramming: From Metabolic Profiling to Drug Targets for Cardiorenal Disease
Sepiso Masenga †, Mulungushi University
The Cardiovascular Metabolic Syndrome, Mechanism and Burden of Obesity and Diabetes
The Cardiovascular Metabolic Syndrome, Mechanism and Burden of Obesity and Diabetes
Bei B. Zhang †, Novo Nordisk
Retuning the Incretin System and its Impact on Kidney Physiology and Cellular Function
Retuning the Incretin System and its Impact on Kidney Physiology and Cellular Function
Jennifer Schaub †, University of Michigan
Treatment Responses to SGLT2 Inhibitors, Defined a Cell at a Time
Treatment Responses to SGLT2 Inhibitors, Defined a Cell at a Time
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Primary Glomerular Diseases Driving CKD: Insight into a Rapidly Evolving Targeted Therapy Landscape
5:00–7:00 PM
Brad H. Rovin †, Ohio State University College of Medicine
Lupus
Lupus
Chee Kay Cheung †, University of Leicester
The Right Drug for the Right IgAN in 2025
The Right Drug for the Right IgAN in 2025
Julie Lin †, Sanofi
Platform Trials in FSGS: Targeting Multiple Aspects of Inflammatory Drivers
Platform Trials in FSGS: Targeting Multiple Aspects of Inflammatory Drivers
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 4, 2026
Breakfast
7:00–8:00 AM
Genes and Kidney; Unique Opportunities for Targeted Therapies, Lessons Learned from ApoL1
8:00–11:00 AM
Michael J. Caplan †, Yale University
Polycystic Kidney Disease: The Journey from Gene to Therapies
Polycystic Kidney Disease: The Journey from Gene to Therapies
Martin Pollak †, Beth Israel Deaconess Medical Center
ApoL1 Biology and Kidney Disease
ApoL1 Biology and Kidney Disease
Dwomoa Adu †, University of Ghana Medical School
ApoL1 Across Continents, Lessons Learned on Gene Environment Interaction in H3 Africa KDRN
ApoL1 Across Continents, Lessons Learned on Gene Environment Interaction in H3 Africa KDRN
Opeyemi Olabisi †, Duke University
From Gene to Trials, Updates on Mode of Action of Ongoing Interventional
From Gene to Trials, Updates on Mode of Action of Ongoing Interventional
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Precision Clinical Trial Strategies for Kidney Disease
5:00–6:45 PM
Matthias Kretzler, University of Michigan
NEPTUNE Match: Lessons Learned from Precision Medicine Glomerular Disease Platform
NEPTUNE Match: Lessons Learned from Precision Medicine Glomerular Disease Platform
Maria Chiara Magnone, Janssen Inc.
Platform Trials in CKD, State of the Art in 2026
Platform Trials in CKD, State of the Art in 2026
Hiddo Lambers Heerspink, University Medical Center Groningen
Precision Medicine Trials in CKD: Report from the Trenches
Precision Medicine Trials in CKD: Report from the Trenches
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Monday, January 5, 2026
Departure
12:00–11:59 PM
Subscribe for Updates